Rinri Therapeutics is a technology company.
Rinri Therapeutics has raised $14.0M across 2 funding rounds.
Rinri Therapeutics has raised $14.0M in total across 2 funding rounds.
# Rinri Therapeutics: A Clinical-Stage Biotech Pioneer in Regenerative Hearing Restoration
Rinri Therapeutics is not a technology company in the traditional sense, but rather a clinical-stage biotechnology company developing regenerative cell therapies to treat sensorineural hearing loss.[1][2] The company is advancing the world's first stem cell-based approaches to restore hearing by replacing damaged or lost sensory cells in the inner ear, targeting a condition affecting over 500 million people globally for which no pharmaceutical treatments currently exist.[2]
What it builds: Rinri develops regenerative cell therapies, with Rincell-1 as its lead product candidate expected to enter clinical trials soon.[2] The company's approach uses exogenous stem cell therapy to restore cochlear function and reverse hearing loss rather than relying on palliative devices like hearing aids or cochlear implants.[1]
Who it serves: Patients with sensorineural hearing loss—the most common sensory disability affecting over 90% of people aged 70 and beyond, with approximately 350 million people globally experiencing disabling hearing loss.[1]
Problem solved: Hearing loss caused by damage to specialized sensory cells in the inner ear currently has no approved pharmaceutical treatments, only limited medical interventions offering poor patient outcomes.[1] Rinri addresses this unmet clinical need by attempting to reverse the condition through cellular regeneration rather than compensation.
Growth momentum: The company is positioned as "the world's leading company to explore the potential of regenerative cell therapy for sensorineural hearing loss" and notably the only company addressing neural hearing loss.[2]
Founding: Rinri Therapeutics was established in 2018 in Sheffield, UK, as a spin-out from the University of Sheffield.[1][4] The company is registered as a private limited company (Company number 11680455) with its registered office at The Innovation Centre, 217 Portobello, Sheffield.[6]
Leadership: Dr. Simon Chandler serves as Chief Executive Officer, bringing deep sector knowledge from blue-chip biotechnology and pharmaceutical companies, as well as experience in early-stage venture building and deep-tech investment from his previous role at IP Group.[2] This background positions the company to navigate both scientific development and commercialization challenges.
Academic foundation: The company's emergence from University of Sheffield research grounds it in peer-reviewed science, providing credibility for its regenerative medicine approach and access to ongoing academic partnerships.
Rinri operates within the broader regenerative medicine and advanced therapeutics sector, riding the wave of increased investment and scientific progress in stem cell therapies. The timing is significant: as the global population ages, age-related hearing loss becomes an increasingly pressing public health issue affecting quality of life for hundreds of millions.
The company represents a shift in how the biotech industry approaches chronic sensory conditions—moving from palliative management to curative regenerative approaches. Success in hearing restoration could establish a template for treating other sensory deficits and validate stem cell therapies for conditions previously considered irreversible. Rinri's work also influences the broader ecosystem by demonstrating how academic research can be translated into clinical-stage therapeutics through university spin-outs, a model increasingly important for deep-tech commercialization.
Rinri stands at an inflection point: the transition from preclinical development to clinical trials will be critical in validating whether regenerative cell therapy can meaningfully restore hearing in human patients. Success would represent a paradigm shift in treating one of humanity's most common sensory disabilities and could unlock significant commercial opportunity in a market currently dominated by hearing device manufacturers.
The company's trajectory will be shaped by clinical trial outcomes, regulatory pathways for cell therapies, manufacturing scalability, and reimbursement models for regenerative medicines. If Rincell-1 demonstrates safety and efficacy, Rinri could catalyze a new category of hearing loss treatment and establish itself as a leader in sensory regeneration—transforming not just the hearing loss market but the broader regenerative medicine landscape.
Rinri Therapeutics has raised $14.0M in total across 2 funding rounds.
Rinri Therapeutics's investors include Boehringer Ingelheim Venture Fund, Oxford Science Enterprises.
Rinri Therapeutics has raised $14.0M across 2 funding rounds. Most recently, it raised $12.0M Venture Round in April 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2021 | $12.0M Venture Round | Boehringer Ingelheim Venture Fund, Oxford Science Enterprises | |
| May 1, 2019 | $2.0M Seed | Oxford Science Enterprises |